ABSTRACT
This study aims to mine the regularity of traditional Chinese medicine(TCM) prescriptions for sick sinus syndrome(SSS) and provide a reference for clinical syndrome differentiation and treatment. The relevant papers were retrieved from CNKI, Wanfang, VIP, and SinoMed with the time interval from inception to January 31, 2023. The relevant information from qualified papers was extracted to establish a library. Lantern 5.0 and Rstudio were used to analyze the latent structure and association rules of TCMs with the frequency ≥3%, which combined with frequency descriptions, were used to explore the rules of TCM prescriptions for SSS. A total of 192 TCM prescriptions were included, involving 115 TCMs with the cumulative frequency of 1 816. High-frequency TCMs include Aconiti Lateralis Radix Praeparata, Ginseng Radix et Rhizoma, Glycyrrhizae Radix et Rhizoma, Astragali Radix, and Salviae Miltiorrhizae Radix et Rhizoma. The high-frequency medicines mainly had the effects of tonifying, releasing exterior with pungent-warm, and activating blood and resolving stasis. The analysis of the latent structure model yielded 13 hidden variables, 26 hidden classes, 8 comprehensive cluster models, and 21 core prescriptions. Accordingly, the common syndromes of SSS were inferred as heart-Yang Qi deficiency, heart-spleen Yang deficiency, heart-kidney Yang deficiency, Yang deficiency and blood stasis, both Qi and Yin deficiency and blood stasis, and Yin and Yang deficiency. The analysis of association rules predicted 30 strong association rules, among which Ginseng Radix et Rhizoma-Aconiti Lateralis Radix Praeparata had the highest support. SSS is a syndrome with Yang deficiency and Qi deficiency as the root causes and cold, phlegm, and stasis as the manifestations. The clinical treatment of SSS should focus on warming Yang and replenishing Qi, which should be supplemented with the therapies of activating blood and resolving stasis, warming interior and dissipating cold, or regulating Qi movement for resolving phlegm according to the patients' syndromes.
Subject(s)
Aconitum , Drugs, Chinese Herbal , Panax , Humans , Sick Sinus Syndrome/drug therapy , Yang Deficiency/drug therapy , Drugs, Chinese Herbal/pharmacology , Medicine, Chinese Traditional , Prescriptions , Rhizome/chemistryABSTRACT
Cardiological and oncological patients comprise the majority of patients admitted to the emergency unit with chronic or acute conditions that are the dominant cause of death worldwide. However, electrotherapy and implantable devices (pacemakers and cardioverters) improve the prognosis of cardiological patients. We present the case report of a patient who, in the past, had a pacemaker implanted due to symptomatic sick sinus syndrome (SSS) without removing the two remaining leads. Echocardiography revealed severe tricuspid valve regurgitation. The tricuspid valve septal cusp was in a restricting position due to the two ventricular leads passing through the valve. A few years later, she was diagnosed with breast cancer. We present a 65-year-old female admitted to the department due to right ventricular failure. The patient manifested symptoms of right heart failure, predominated by ascites and lower extremity edema, despite increasing doses of diuretics. The patient underwent a mastectomy two years ago due to breast cancer and was qualified for thorax radiotherapy. A new pacemaker system was implanted in the right subclavian area as the pacemaker generator occupied the radiotherapy field. In the case of right ventricular lead removal and the need for pacing and resynchronization therapy, guidelines allow a coronary sinus for LV pacing to avoid passing the leads through the tricuspid valve. We facilitated this approach in our patient, suggesting that the percentage of ventricular pacing was very low.
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Yixin-Fumai granules (YXFMs)-composed of Ginseng quinquefolium (L.) Alph. Wood, Ophiopogon japonicus (Thunb.) Ker Gawl, Schisandra arisanensis Hayata, Astragalus aaronsohnianus Eig, Salvia cryptantha Montbret & Aucher ex Benth, and Ligusticum striatum DC-are compound granules used in traditional Chinese medicine to increase heart rate and thus treat bradyarrhythmia. It may be effective in treating sick sinus syndrome (SSS). AIM: To observe the effect of YXFMs on aging-induced SSS in mice and explore whether this effect is related to the Nrf-2/HO-1 signaling pathway. MATERIALS AND METHODS: Mice with a significant decrease in the heart rate due to natural aging were selected to construct an SSS model. After the mice were administered YXFMs, the damage to their sinoartrial node (SAN) was assessed through electrocardiography, Masson's trichrome staining, and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Dihydroethidium staining and immunofluorescence staining were used to assay reactive oxygen species (ROS) content and HCN4, respectively. Moreover, to observe the effects of YXFMs in vitro, the HL-1 cell line, derived from mouse atrial myocytes, was used to simulate SAN pacemaker cells, with H2O2 used as the cellular oxidative stress (OS) inducer. 2,7-Dichlorodihydrofluorescein diacetate staining was used to assay ROS content, whereas immunofluorescence staining and Western blotting were used to elucidate the related protein expression. Finally, mice were injected the Nrf-2 inhibitor ML385 to reversely verify the effects of YXFMs. RESULTS: In our in vivo experiments, YXFMs significantly inhibited aging-induced SSS, shortened the R-R interval, increased heart rate, alleviated fibrosis, reduced apoptosis rate and ROS content, and promote HCN4 expression in the SAN. In our in vitro experiments, YXFMs significantly inhibited H2O2-induced cell peroxidation damage, promoted Nrf-2 activation and nuclear metastasis, increased HO-1 expression- thereby inhibiting ROS accumulation-and finally, upregulated HCN4 expression through the inhibition of histone deacetylase 4 (HDAC4) expression and its nuclear metastasis. Finally, injection of the Nrf-2 inhibitor ML385 after YXFMs administration inhibited their protective effect in the mice. CONCLUSION: Here, we elaborated on the relationship between aging-induced SSS and the Nrf-2/HO-1 pathway for the first time and proposed that YXFMs improve SSS via the Nrf-2/HO-1 axis. Specifically, YXFMs promoted Nrf-2 activation and plasma-nuclear transfer to enhance HO-1 expression via the Nrf-2/HO-1 axis. This inhibited OS and reduced ROS accumulation in the SAN, and then, through the ROS/HDAC4 axis, reduced HDAC4 expression and plasma-nuclear transfer. Thereby, the OS-induced HCN4 loss in the SAN was inhibited-improving the function of If channel and thus producing SAN protection effect against SSS and improving the heart rate and R-R interval. In the future, we plan to use bioinformatics analysis technology to execute the next step of our research, namely to determine the effect of isolated, purified components of YXFMs in SSS, to increase its efficiency and reduce the toxicity of YXFMs.
Subject(s)
Drugs, Chinese Herbal/pharmacology , Heme Oxygenase-1/metabolism , Membrane Proteins/metabolism , NF-E2-Related Factor 2/metabolism , Sick Sinus Syndrome/drug therapy , Aging , Animals , Apoptosis/drug effects , Female , Male , Mice , Mice, Inbred C57BL , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism , Sick Sinus Syndrome/physiopathology , Signal Transduction/drug effectsSubject(s)
Bradycardia , Cardiac Conduction System Disease , Cardiac Resynchronization Therapy/methods , Cardiac Surgical Procedures , Cardiovascular Agents/pharmacology , Electrophysiologic Techniques, Cardiac/methods , Quality of Life , American Heart Association , Bradycardia/etiology , Bradycardia/physiopathology , Bradycardia/therapy , Cardiac Conduction System Disease/etiology , Cardiac Conduction System Disease/physiopathology , Cardiac Conduction System Disease/therapy , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/methods , Heart Rate/drug effects , Heart Rate/physiology , Humans , Patient Care Management/methods , Patient Selection , Practice Guidelines as Topic , United StatesSubject(s)
Bradycardia , Cardiac Conduction System Disease , Cardiac Resynchronization Therapy/methods , Cardiac Surgical Procedures , Cardiovascular Agents/pharmacology , Electrophysiologic Techniques, Cardiac/methods , Quality of Life , American Heart Association , Bradycardia/etiology , Bradycardia/physiopathology , Bradycardia/therapy , Cardiac Conduction System Disease/etiology , Cardiac Conduction System Disease/physiopathology , Cardiac Conduction System Disease/therapy , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/methods , Heart Rate/drug effects , Heart Rate/physiology , Humans , Patient Care Management/methods , Patient Selection , United StatesABSTRACT
The efficacy of pulmonary vein antral isolation for patients with prolonged sinus pauses (PSP) on termination of atrial fibrillation has been reported. We studied the right atrial (RA) electrophysiologic and electroanatomic characteristics in such patients. Forty patients underwent electroanatomic mapping of the RA: 13 had PSP (group A), 13 had no PSP (group B), and 14 had paroxysmal supraventricular tachycardia (control group C). Group A had longer P-wave durations in lead II than did groups B and C (115.5 ± 15.4 vs 99.5 ± 10.9 vs 96.5 ± 10.4 ms; P=0.001), and RA activation times (106.8 ± 13.8 vs 99 ± 8.7 vs 94.5 ± 9.1 s; P=0.02). Group A's PP intervals were longer during adenosine triphosphate testing before ablation (4.6 ± 2.3 vs 1.7 ± 0.6 vs 1.5 ± 1 s; P <0.001) and after ablation (4.7 ± 2.5 vs 2.2 ± 1.4 vs 1.6 ± 0.8 s; P <0.001), and group A had more complex electrograms (11.4% ± 5.4% vs 9.3% ± 1.6% vs 5.8% ± 1.6%; P <0.001). Compared with group C, group A had significantly longer corrected sinus node recovery times at a 400-ms pacing cycle length after ablation, larger RA volumes (100.1 ± 23.1 vs 83 ± 22.1 mL; P=0.04), and lower conduction velocities in the high posterior (0.87 ± 0.13 vs 1.02 ± 0.21 mm/ms; P=0.02) and high lateral RA (0.89 ± 0.2 vs 1.1 ± 0.35 mm/ms; P=0.04). We found that patients with PSP upon termination of atrial fibrillation have RA electrophysiologic and electroanatomic abnormalities that warrant post-ablation monitoring.
Subject(s)
Atrial Fibrillation/diagnosis , Atrial Fibrillation/surgery , Atrial Function, Right , Electrophysiologic Techniques, Cardiac , Pulmonary Veins/surgery , Sinoatrial Node/physiopathology , Action Potentials , Adenosine Triphosphate/administration & dosage , Aged , Atrial Fibrillation/physiopathology , Cardiac Pacing, Artificial , Catheter Ablation , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Pulmonary Veins/physiopathology , Recovery of Function , Time Factors , Treatment OutcomeABSTRACT
Pacemaker activity of the sino-atrial node generates the heart rate. Disease of the sinus node and impairment of atrioventricular conduction induce an excessively low ventricular rate (bradycardia), which cannot meet the needs of the organism. Bradycardia accounts for about half of the total workload of clinical cardiologists. The 'sick sinus' syndrome (SSS) is characterized by sinus bradycardia and periods of intermittent atrial fibrillation. Several genetic or acquired risk factors or pathologies can lead to SSS. Implantation of an electronic pacemaker constitutes the only available therapy for SSS. The incidence of SSS is forecast to double over the next 50 years, with ageing of the general population thus urging the development of complementary or alternative therapeutic strategies. In recent years an increasing number of mutations affecting ion channels involved in sino-atrial automaticity have been reported to underlie inheritable SSS. L-type Cav 1.3 channels play a major role in the generation and regulation of sino-atrial pacemaker activity and atrioventricular conduction. Mutation in the CACNA1D gene encoding Cav 1.3 channels induces loss-of-function in channel activity and underlies the sino-atrial node dysfunction and deafness syndrome (SANDD). Mice lacking Cav 1.3 channels (Cav 1.3-/- ) fairly recapitulate SSS and constitute a precious model to test new therapeutic approaches to handle this disease. Work in our laboratory shows that targeting G protein-gated K+ (IKACh ) channels effectively rescues SSS of Cav 1.3-/- mice. This new concept of 'compensatory' ion channel targeting shines new light on the principles underlying the pacemaker mechanism and may open the way to new therapies for SSS.
Subject(s)
Calcium Channels, L-Type/metabolism , Channelopathies/metabolism , Heart Ventricles/metabolism , Animals , Bradycardia/genetics , Bradycardia/metabolism , Bradycardia/physiopathology , Calcium Channels, L-Type/genetics , Channelopathies/genetics , Channelopathies/physiopathology , Heart Rate/genetics , Heart Rate/physiology , Heart Ventricles/physiopathology , Humans , Mutation/genetics , Sick Sinus Syndrome/genetics , Sick Sinus Syndrome/metabolism , Sick Sinus Syndrome/physiopathology , Sinoatrial Node/metabolism , Sinoatrial Node/physiopathologyABSTRACT
Objective To observe the clinical therapeutic efficacy of prescription of supplementing qi and activating yang on sick sinus syndrome. Methods According to the random number table, 231 patients with sick sinus syndrome were randomly divided into treatment group and control group. One hundred and fifty patients in the treatment group were given the Chinese herbal medicine while the other 81 patients in the control group were given atropine. The therapeutic course was four weeks in each group. The changes of clinical manifestations and electrocardiogram (24 h Holter monitoring ECG) of two groups were compared. Results The total effectiveness of treatment group was 98.67% (148/150), the control group was 41.98% (34/81), there was a significant difference in the clinical curative efficacy (P<0.01). The total effective rate of the treatment group was 87.3%(131/150) and that of the control group was 35.9%(29/81), and the average increases of heart rates in 24 hours were 9/min and 4/min, respectively. There was significant difference between the two groups (P <0.05). Conclusion The prescription of supplementing qi and activating yang was effective in improving the clinical symptoms and heart rates of patients with sick sinus syndrome.
ABSTRACT
Objective To observe the difference clinical therapeutic efficacy of the Chinese herbal medicine and western medicine on sick sinus syndrome patients.Method 171 patients with sick sinus syndrome were randomly divided into treatment group and control group.90 patients in the treatment group were given Qiangxin Fumai Mixture while the other 81 patients in the control group were given atropine.The therapeutic course was four weeks in each group.The changes of clinical manifestations,electrocardiogram(24 h Holter monitoring ECG) and left ventricular ejection fraction(LVEF) were compared between two groups.Result Clinical therapeutic efficacy:There was significant difference between two groups(P